Lactobacillus paracasei TK1501 fermented soybeans alleviate dextran sulfate sodium-induced colitis by regulating...

Area of Science:

• Microbiology
• Immunology
• Gastroenterology

Background:

• Probiotic foods offer health benefits but have short shelf lives and demanding preservation conditions due to fragile live bacteria.
• Investigated fermented foods for inflammatory bowel disease (IBD) treatment independent of live bacteria, focusing on underlying mechanisms.
• Utilized dextran sulfate sodium-induced colitis model in mice, treating with Lactobacillus paracasei TK1501 fermented soybeans and their metabolites.

Purpose of the Study:

• To evaluate the efficacy of TK1501 fermented soybean in treating inflammatory bowel disease (IBD).
• To determine if the therapeutic effects are attributed to live bacteria, dead bacteria, or bacterial metabolites.
• To identify the key active components responsible for the observed health benefits.

Main Methods:

• Induced inflammatory bowel disease (IBD) in mice using dextran sulfate sodium.
• Administered Lactobacillus paracasei TK1501 fermented soybeans and their metabolites to treat the induced colitis.
• Performed compositional analysis of soybeans before and after fermentation.
• Conducted cell experiments to investigate the effects of lipoteichoic acid on macrophages.

Main Results:

• TK1501 fermented soybean significantly alleviated colitis in mice.
• The therapeutic efficacy was linked to bacterial metabolites, not live or dead bacteria.
• Identified lipoteichoic acid and peptidoglycan as primary active ingredients, with lipoteichoic acid reducing colonic macrophages and peptidoglycan potentially increasing mucin-2 expression.
• Lipoteichoic acid was shown to enhance macrophage phagocytosis in cell experiments.

Conclusions:

• The anti-inflammatory effects of TK1501 fermented soybean on colitis are mediated by its metabolites, specifically lipoteichoic acid and peptidoglycan.
• This fermented food offers potential for a long shelf life and relaxed storage conditions, making it a viable alternative to traditional probiotics.
• The findings highlight the therapeutic potential of bacterial metabolites in managing inflammatory bowel disease.